Company Directory - Humacyte, Inc.
Company Details - Humacyte, Inc.
Humacyte, Inc.
WebsiteHumacyte, Inc. is a biotechnology company focused on regenerative medicine applications and manufacturing tissue-based products.
CCI Score
CCI Score: Humacyte, Inc.
-38.49
0.02%
Latest Event
Humacyte Inc Lobbying Spending and Corporate Political Influence
In 2024, Humacyte Inc spent $60,000 on lobbying efforts, a data point that raises concerns about the company's role in influencing public policy and safeguarding its interests. From a left-leaning perspective, even modest lobbying can amplify corporate power and potentially facilitate favorable regulatory conditions, contributing to broader trends of corporate complicity in undermining democratic accountability.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
TOADIE
Humacyte, Inc. is currently rated as a Toadie.
Latest Events
- DEC312024
In 2024, Humacyte Inc spent $60,000 on lobbying efforts, a data point that raises concerns about the company's role in influencing public policy and safeguarding its interests. From a left-leaning perspective, even modest lobbying can amplify corporate power and potentially facilitate favorable regulatory conditions, contributing to broader trends of corporate complicity in undermining democratic accountability.
-10
Political Contributions and Lobbying Efforts
March 26
The lobbying activity, with a reported spending of $60,000 in 2024, indicates that Humacyte Inc is engaging in corporate political behavior. While the amount is relatively modest compared to larger corporations, such efforts are viewed through a left-leaning lens as a means to secure favorable policy environments that can undermine democratic oversight and contribute to patterns of corporate complicity in authoritarian practices. The reliance on lobbying to achieve political objectives raises questions about transparency and the potential for shifting policy in ways that benefit corporate interests over public welfare.
- DEC032024
A class action lawsuit filed against Humacyte alleges that the company and its executives failed to disclose significant regulatory and manufacturing compliance issues, raising serious concerns over its business practices and ethical responsibility.
-60
Business Practices and Ethical Responsibility
March 26
The lawsuit alleges that Humacyte misled investors by not disclosing material adverse facts related to its manufacturing compliance, including quality assurance deficiencies and inadequate microbial testing. Such actions point to poor corporate governance and a significant lapse in ethical responsibility in business practices.
- OCT292024
Humacyte, Inc. is under shareholder scrutiny following revelations of FDA compliance issues at its Durham facility. The misrepresentations regarding microbial quality assurance and safety protocols have raised serious concerns about the company’s ethical business practices and transparency.
-40
Business Practices and Ethical Responsibility
March 26
The company's assurances regarding a smooth regulatory pathway were contradicted by FDA findings citing critical lapses in microbial quality testing. This misrepresentation undermines ethical business practices and transparency, damaging investor trust and reflecting negatively on its commitment to responsible operations.
Humacyte (HUMA) Faces Shareholder Scrutiny After FDA Compliance Issues
- OCT172024
A class action lawsuit alleges that Humacyte, Inc. failed to disclose critical deficiencies in its manufacturing practices, including lack of microbial testing and inadequate quality oversight, which were highlighted during FDA inspections. This has led to significant investor losses and raised concerns about the company's ethical business practices.
-60
Business Practices and Ethical Responsibility
March 26
The class action lawsuit against Humacyte, Inc. underscores serious allegations that the company misled investors by failing to disclose major manufacturing and quality control deficiencies. The revelations about inadequate microbial testing, lack of proper quality oversight, and FDA inspection violations point to a significant lapse in ethical responsibility, negatively impacting investor trust and business integrity.
- AUG092024
Humacyte, Inc. is under scrutiny following FDA investigations that revealed significant violations of good manufacturing practices at its Durham, North Carolina facility. This non-compliance has had a negative impact on product safety and investor confidence.
-50
Business Practices and Ethical Responsibility
March 26
Humacyte, Inc.'s failure to comply with mandated good manufacturing practices, as evidenced by FDA investigations, calls into question its ethical responsibility and business practices. The significant deficiencies in quality assurance and testing protocols suggest a disregard for regulatory standards that protect public health and investor interests.
Understanding the Legal Landscape for Humacyte Investors - Investors Hangout
- DEC312021
Data from OpenSecrets reveals that Humacyte Inc spent $110,000 on lobbying efforts in 2021, highlighting corporate involvement in influencing political processes. This expenditure contributes to concerns over the company’s role in shaping policies in favor of corporate interests, which may undermine democratic accountability and support authoritarian outcomes.
-30
Political Contributions and Lobbying Efforts
March 26
Humacyte Inc's spending of $110,000 on lobbying in 2021, as detailed by OpenSecrets, indicates deliberate efforts to influence political decisions. From an anti-fascist perspective, such financial engagement is concerning because it can enable sway over democratic institutions and support policies that favor corporate interests over public accountability.
Alternatives
Corporation
0.00
San Carlos, United States
-24.95
Cambridge, USA
-43.03
Corporation
0.00
Corporation
-29.73
Corporation
19.47
Corporation
0.00
Thousand Oaks, USA
13.63
Somerset, United States
1.18
Cambridge, United States
0.27
Industries
- 325414
- Biological Product (except Diagnostic) Manufacturing
- 541715
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- 621511
- Medical Laboratories